Cancer Care Engineering Colorectal Cancer

Gabriela Chiorean, M.D.

May 27, 2011

Rationale

Perform OMICs of healthy, polyps, cancer

Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools

Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers

Schema IUCRO-0221CCE in CRC

SAMPLES

Blood (Serum)7 mL red top

Metabolomics, vit D

Blood (Plasma)21 mL purple top

Genomics, lipidomics, glycoproteomics

N=810

Stratification:- Healthy

(n=270)- Polyps

(n=270)- Cancer

(n=270)

stg 1/2

stg 3

stg 4 metastatic

Fresh Tissue10 mg polyp or50 mg cancer /

50 mg normal tissue

SHIP

DRY

ICE

8-hr fasting

Paraffin-Embedded TissueMSI, methylation, KRAS, BRAF, p53

Samples Collection Healthy Controls

Screening Colonoscopy – GI Clinic

Label specimensHealthy

if no polyps/tumor

Blood Questionnaires

N= 5 6/2009N=74 5/2010N=109 5/2011

Samples Collection Adenomatous Polyps

Screening Colonoscopy – GI Clinic

Label specimensPolyp

Polyps identified

Tissue procurement/Research specialist -Polyp cut in ½

-Place in tube with no preservative-Freeze at -70oC

Blood Questionnaires

N= 3 6/2009N= 65 5/2010N= 96 5/2011

Samples Collection Cancer

Surgery

Tissue:tumor, normal mucosa

Blood Questionnaires

Chemotherapy Follow-up

Every 3 months Up to 24 months

N= 8 6/2009 N= 34 5/2010N= 55 5/2011

Sample Acquisition4/2009-5/2011

Cancer total No prior chemo Prior chemo

n=55 n=26 n=29 Stage 1 n=6 n=6 0Stage 2 n=3 n=2 n=1Stage 3 n=17 n=10

n=7Stage 4 n=29 n=8 n=21